(Q34729781)

4 August 2017

1 reference

title

The placebo effect and randomized trials: analysis of conventional medicine (English)

1 reference

4 August 2017

0 references

1 reference

Mark A Moyad

1

1 reference

4 August 2017

language of work or name

1 reference

1 February 2002

1 reference

Urologic Clinics of North America

4 August 2017

published in

1 reference

4 August 2017

volume

29

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

125-33, ix-x

1 reference

What can randomized controlled trials tell us about nutrition and cancer prevention?

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

1 reference

7 January 2021

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Allergic rhinitis update: Epidemiology and natural history.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

The placebo effect in asthma drug therapy trials: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Use of topical minoxidil therapy for androgenetic alopecia in women

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Treatment of female androgenetic alopecia with minoxidil 2%

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Australian trial of topical minoxidil and placebo in early male pattern baldness

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Androgenetic alopecia: treatment results with topical minoxidil

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Finasteride: a review of its use in male pattern hair loss

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Transdermal testosterone treatment in women with impaired sexual function after oophorectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Sex, hormones, and hysterectomies.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Symptoms in gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Menopausal Flushing: Double-blind Trial of a Non-hormonal Medication

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Megestrol Acetate for the Prevention of Hot Flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

The direct health care costs of obesity in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Increasing prevalence of overweight and obesity among Spanish adults, 1987-1997

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Demonstration to medical students of placebo responses and non-drug factors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

The powerful placebo effect: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

Is there logic in the placebo?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

General practice consultations: is there any point in being positive?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2802%2900038-1

7 January 2021

10.1016/S0094-0143(02)00038-1

Identifiers

DOI

1 reference

4 August 2017

1 reference